| Name | Title | Contact Details |
|---|
Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.
Linnaeus Therapeutics is a development stage biotech company engaged in the identification and development of small molecule agents for the treatment of cancer. Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016. Linnaeus is based upon discoveries from the Ridky lab at the University of Pennsylvania.
Crown bioscience is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We`re building partnerships and transforming care. Alternate Solutions Health Network was founded in 1999 by David and Tessie Ganzsarto. We collaborate with health systems in joint venture partnerships to create a post-acute care solution, delivering efficient centralized operations and utilizing a best-in-class software platform. Our company has been dedicated, since the very beginning, to transforming the quality of care for both our partners and our patients. Our partnerships are built upon four cornerstones for maximizing quality outcomes and financial performance: Growth, Profitability, Quality Outcomes & Satisfaction, Compliance. By utilizing a centralized operational model we`re able to deliver the highest level of efficiency to our partners. Our model is uniquely suited for success in at-risk and value-based reimbursement models with payers, hospitals and other providers.
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.